Literature DB >> 10792114

Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury.

M T Donnelly1, A F Goddard, B Filipowicz, S V Morant, M J Shield, C J Hawkey.   

Abstract

INTRODUCTION: The harmful effects of non-steroidal anti-inflammatory drugs (NSAIDs) on the gastric mucosa and the prophylactic effects of misoprostol are both dose-dependent. AIM: To investigate whether a low-dose of misoprostol is sufficient to prevent gastric mucosal injury caused by low-dose aspirin.
METHODS: We conducted a double-blind placebo controlled parallel group endoscopic study in 32 evaluable volunteers. The main outcome measure was erosive injury (ulcers and superficial erosions) in the gastric mucosa over 28 days.
RESULTS: Most subjects developed erosions on aspirin 300 mg daily. This was significantly reduced by misoprostol 100 microg daily. (Odds ratio 0.18, 95% CI: 0.07-0.48). There were no drug-related or gastrointestinal adverse events in subjects receiving misoprostol.
CONCLUSION: Misoprostol 100 microg daily can prevent low-dose aspirin induced gastric mucosal injury without causing identifiable adverse effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792114     DOI: 10.1046/j.1365-2036.2000.00739.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Upper gastrointestinal complications induced by anti-platelet agents.

Authors:  Takashi Kawai; Hiroko Sugimoto; Mari Fukuzawa; Masakatsu Fukuzawa; Chika Kusano; Takuji Gotoda; Fuminori Moriyasu
Journal:  Clin J Gastroenterol       Date:  2013-08-13

2.  Gastric acid secretion level modulates the association between Helicobacter pylori infection and low-dose aspirin-induced gastropathy.

Authors:  Katsunori Iijima; Nobuyuki Ara; Yasuhiko Abe; Tomoyuki Koike; Wataru Iwai; Kaname Uno; Naoki Asano; Akira Imatani; Shuichi Ohara; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2011-02-26       Impact factor: 7.527

Review 3.  Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.

Authors:  Angel Lanas; Carla J Gargallo
Journal:  J Gastroenterol       Date:  2015-01-17       Impact factor: 7.527

4.  Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction.

Authors:  Ravi Vachhani; Doumit Bouhaidar; Alvin Zfass; Bimaljit Sandhu; Ali Nawras
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

5.  Poor awareness of preventing aspirin-induced gastrointestinal injury with combined protective medications.

Authors:  Ling-Ling Zhu; Ling-Cheng Xu; Yan Chen; Quan Zhou; Su Zeng
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

6.  Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin.

Authors:  Harald Vonkeman; Inger Meek; Mart van de Laar
Journal:  Drug Healthc Patient Saf       Date:  2010-10-06

7.  The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries.

Authors:  Jing Zhao; Yihong Fan; Wu Ye; Wen Feng; Yue Hu; Lijun Cai; Bin Lu
Journal:  Gastroenterol Res Pract       Date:  2019-06-18       Impact factor: 2.260

8.  Obstructive Jaundice Due to Duodenal Ulcer Induced by Lenvatinib Therapy for Hepatocellular Carcinoma.

Authors:  Maito Suoh; Atsushi Hagihara; Masafumi Yamamura; Hirotsugu Maruyama; Koichi Taira; Masaru Enomoto; Akihiro Tamori; Yasuhiro Fujiwara; Norifumi Kawada
Journal:  Intern Med       Date:  2020-10-07       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.